Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2

Oncology

Volumn 60, Issue 4, 2001, Pages 308-312

  Lissoni, Paolo ^a   Mandalà, Mario ^b   Curigliano, Giuseppe ^b   Ferretti, Gianluigi ^b   Moro, Cecilia ^a   Ardizzoia, Antonio ^a   Malugani, Fabio ^a   Tancini, Gabriele ^a   Tisi, Elisabetta ^a   Arrigoni, Carlo ^a   Barni, Sandro ^c  

^a SAN GERARDO HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Treviglio Caravaggio Hospital   (Italy)

Author keywords

Interleukin 2; Intracavitary therapy; Neoplastic effusions; Palliative treatment

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG TOLERABILITY; EFFUSION; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PERICARDIAL EFFUSION; PERICARDIUM; PERITONEAL CAVITY; PERITONEUM EXUDATE; PLEURA CAVITY; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PLEURAL EFFUSION; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17844380760     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058525     Document Type: Article

References (27)

1. Pathogenesis of pleural effusion in the carcinoma of the breast
2. The spread of breast cancer. Importance of the intrathoracic lymphatic route and its relevance to treatment
3. Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining
4. Antigen-presenting function of human peritoneum mesothelial cells
5. Carcinomatous involvement of the pleura
6. Malignant pleural and pericardial effusions
7. Pleural effusion in breast cancer: A review of 105 cases
8. Intrapleural chemotherapy for effusion from metastatic breast carcinoma
9. Malignant ascites. Clinical and experimental observations
10. Malignant effusions and their management
11. Intracavitary bleomycin in the management of malignant effusions
12. Intrapleural tetracycline in malignant pleural effusions. A randomized study
13. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin
14. Tetracycline pleurodesis for malignant pleural effusions. A 10-year retrospective study
15. Bleomycin pharmacokinetics in man: Intracavitary administration
16. Intrapleural therapy for malignant pleural effusion: A randomized comparison of bleomycin and tetracycline
17. Interferon alpha-2b in the treatment of pleural and peritoneal neoplastic effusions
18. Intrapleural natural beta interferon in the treatment of malignant pleural effusions
19. Intraperi-toneal (i.p.) application of recombinant human tumor necrosis factor (rHn-TNF) as an effective palliative treatment of malignant ascites from ovarian cancer and gastroenteropancreatic carcinomas
20. Induction of lymphokine-activated killer cells by intrapleural instillation of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer
21. Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions
22. Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions
23. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion
24. Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: A randomized study
25. Malignant pleural effusion
26. Interleukin-2 administration intravenous and intrapleurally in a patient with primary pulmonary adenocarcinoma
27. Clinical experience using immunotherapy (IL-2/LAK cells or interferon alpha 2a) in malignant mesothelioma